Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CytoMed Therapeutics Limited ( (GDTC) ) just unveiled an announcement.
On April 28, 2025, CytoMed Therapeutics Limited announced its financial results for the year ending December 31, 2024, alongside clinical and corporate updates. The company reported a 39% reduction in net loss compared to the previous year, attributed to lower IPO-related expenses and reduced insurance and investor relations costs. CytoMed is advancing its clinical trials, including the ANGELICA trial in Singapore and a Phase II trial in India, and is expanding its operations with a focus on gamma delta T cells and iPSC-derived therapies. The acquisition of a licensed cord blood bank in Malaysia marks a strategic move into cord blood-derived therapeutics, with plans for future expansion and partnerships in China and India.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
GDTC’s overall stock score is moderate due to its strong technical momentum and a robust balance sheet. However, significant operational losses, negative cash flow, and a lack of earnings guidance limit its attractiveness. The company’s valuation challenges further impact the score, reflecting the need for improved financial performance and strategic clarity.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that focuses on developing novel, affordable donor-derived, cell-based allogeneic immunotherapies. The company aims to serve the ASEAN region and North Asia by leveraging Asia’s low-cost infrastructure to produce GMP-grade immune cells for treating cancers and autoimmune diseases.
YTD Price Performance: -34.86%
Average Trading Volume: 20,199
Technical Sentiment Signal: Buy
Current Market Cap: $26.31M
See more insights into GDTC stock on TipRanks’ Stock Analysis page.